- By ICR Secretariat
- Posted Friday, July 8, 2022
Novartis, staring down tough market for M&A, leans toward $25B Sandoz spinoff: Bloomberg
https://www.fiercepharma.com/pharma/novartis-starting-down-tough-market-ma-mulls-sandoz-spinoff-bloomberg
For months, the industry has waited patiently as Novartis mulls the fate of its $25 billion generics arm. Now, it appears a spinoff could be in the cards.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- NICE recommendation expands patient eligibility for AbbVie’s Ozurdex 18/08/2022 03:38 PM
- Amgen’s low tax rates draw attention of top Democratic senator 18/08/2022 03:23 PM
- 2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again 18/08/2022 03:16 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org